Sentiment for Keryx Biopharmaceuticals Inc (NASDAQ:KERX)
Keryx Biopharmaceuticals Inc (NASDAQ:KERX) institutional sentiment decreased to 1.21 in Q2 2015. Its down -0.79, from 2 in 2015Q1. The ratio dropped, as 81 funds increased or opened new holdings, while 67 sold and trimmed positions in Keryx Biopharmaceuticals Inc. The funds in our partner’s database now possess: 90.63 million shares, down from 91.84 million shares in 2015Q1. Also, the number of funds holding Keryx Biopharmaceuticals Inc in their top 10 holdings was flat from 3 to 3 for the same number . Sold All: 28 Reduced: 39 Increased: 60 New Position: 21.
Top Keryx Biopharmaceuticals Inc Holders
Finepoint Capital Lp had the largest stake owing 1.61 million shares as of Q2 2015 for 4.65% of the stocks portfolio. Baupost Group Llc Ma is another quite bullish investment professional who is possessing 25.79 million shares of Keryx Biopharmaceuticals Inc or 4.29% of their stocks portfolio. Further, 1492 Capital Management Llc have 1.67% of their stocks portfolio invested in the company for 264,297 shares. The Massachusetts-based fund Cormorant Asset Management Llc revealed it had purchased so far a stake worth about 1.1% of the investment professional’s stock portfolio in Keryx Biopharmaceuticals Inc. The California-based fund Falcon Point Capital Llc is also positive about the stock, possessing 826,000 shares or 0.85% of their stocks portfolio.
Recent Keryx Biopharmaceuticals Inc Analyst Ratings
Ratings analysis reveals 53% of Keryx Biopharma’s analysts are positive. Out of 15 Wall Street analysts rating Keryx Biopharma, 8 give it “Buy”, 4 “Sell” rating, while 3 recommend “Hold”. The lowest target is $2.50 while the high is $32. The stock’s average target of $13.81 is 332.92% above today’s ($3.19) share price. NASDAQ:KERX was included in 45 notes of analysts from November 17, 2014. Raymond James initiated the shares of Keryx Biopharma in a note on September 9 with “Market Perform” rating. MLV maintained NASDAQ:KERX’s stock on a June 25. MLV has “Buy” rating and $25 PR. Zacks upgraded Keryx Biopharma’s stock on August 28 to “Sell” rating. Cowen & Co initiated it with “Buy” rating and $25 PT in February 9 note. Finally, FBR Capital initiated the shares of Keryx Biopharma with “Mkt Perform” rating in an August 11 note.
